The spinal cord stimulator device market is expected to grow from US$ 2,779.91 million in 2022 to US$ 4,967.52 million by 2030; it is anticipated to record a CAGR of 7.5% from 2022 to 2030.

A spinal cord stimulation device is an implanted device that relieves pain by transmitting low-level electrical signals directly into the spinal cord. The stimulator is mostly used after nonsurgical pain treatments fail to provide sufficient relief. Additionally, the device can improve the overall quality of life and sleep. As it is typically prescribed along with other pain management treatments, it effectively suppresses the need for pain medicines. The spinal cord stimulator device market size is expanding with the rising number of spinal cord injuries (SCIs) and the availability of innovative treatments.

With advancements in medical knowledge and the introduction of effective medicines, various spinal cord stimulators are used in treatments. In addition to the multiple advantages of these devices-including portability, convenience, and effectiveness-the growing number of product approvals and developments is expected to propel the demand for spinal cord stimulator devices in the coming years. A few of the major developments and approvals in the spinal cord stimulator device market are listed below:

- In October 2023, Boston Scientific Corp won approval from the US FDA for the WaveWriter Alpha SCS systems for treating painful diabetic peripheral neuropathy (DPN), a disorder affecting the lower limbs of patients.

- In August 2023, Medtronic plc received CE (Conformit? Europ?enne) Mark for its Inceptiv. The device is a closed-loop rechargeable spinal cord stimulator (SCS). It is the first SCS device of the company to offer a closed-loop feature. Inceptive is equipped with technology that can sense each patient's unique biological signals, adjust stimulation as per the patient's moment, and offer harmonized therapy with the motions of daily life.

- In August 2022, Abbott Laboratories received approval from the US FDA for its Proclaim Plus SCS system to treat chronic pain. The BurstDR stimulation technology enables the device to deliver superior pain relief. It offers FlexBurst360 therapy that offers pain coverage across the trunk and limbs; the device can be programmed per the patient's evolving therapeutic needs.

- In September 2020, Boston Scientific announced the launch of the WaveWriter Alpha portfolio of spinal cord stimulator (SCS) Systems in the European market. The portfolio comprises four MRI, Bluetooth-enabled implantable pulse generators (IPGs), and additional personalization options based on patients' needs. These systems are available in rechargeable/non-rechargeable options, which cover multiple areas of pain.

Thus, such advancements by various market players and product approvals catalyze the growth of the spinal cord stimulator devices market.

According to the National Library of Medicine (NLM), nearly 250,000-500,000 patients suffer from spinal cord injuries (SCIs) every year worldwide. According to a report published by the Association for Spinal Injury Research, Rehabilitation and Reintegration (Aspire, UK), ~2,500 people are diagnosed with SCIs annually in the UK. Currently, ~50,000 people are living with these injuries in the UK. The National Spinal Cord Injury Statistical Center (NSCISC) estimates that ~320,000 people are living with traumatic SCIs in the US. An elevated number of cases is attributed to motocross and motorcycling competitions emerging as the most popular sporting activities worldwide, as per the National Institute of Health (NIH) report.

Moreover, these injuries are common in the elderly population. According to the data presented under the World Bank's collection of development indicators in 2022, 22.41% of the population in Germany is aged above 65 years. An article published by MDPI mentions that the prevalence rate of traumatic SCIs is ~500 per million inhabitants, and the incidence rate surges to 13 per million globally.

SCIs have life-changing impacts on the injured patients and their families. The rising incidence of SCIs and the corresponding treatment of patients in hospitals is followed by at least one readmission of the patient every year. This is because SCIs are not treated at once. The causes of rehospitalization include respiratory and urinary tract infections and fractures occurring during motorcycling sports activities. With rising SCI and the availability of a well-developed infrastructure in treatment centers providing rehabilitation programs, demand for spinal cord stimulation devices is surging in specialized or rehab centers, fueling the growth of the spinal cord stimulator device.

Based on geography, the spinal cord stimulator device market is segmented into North America (US, Canada, and Mexico), Europe (UK, Germany, France, Italy, Spain, Russia, and Rest of Europe), Asia Pacific (China, Japan, India, South Korea, Australia, Southeast Asia, and Rest of Asia Pacific), the Middle East & Africa (UAE, Saudi Arabia, South Africa, and Rest of Middle East & Africa), and South & Central America (Brazil, Argentina, and Rest of South & Central America). North America held the largest share of the global spinal cord stimulator devices market in 2022 owing to technological advancements, increasing spinal cord injuries, government support for expanding the product pipeline, and major market players engaged in new and existing product developments. However, Asia Pacific is anticipated to register the highest CAGR from 2022 to 2030. The US held the largest share of the spinal cord stimulator devices market in North America in 2022. The US market growth is mainly driven by a surging incidence of spinal cord injuries, an increasing number of product launches, and favorable initiatives by governments. According to Spinal Cord Inc., ~18,000 people suffer from spinal cord injuries every year in the US. The National Spinal Cord Injury Statistical Center (NSCISC) states that ~320,000 people are living with traumatic spinal cord injury in the US. In line with the increasing cases of spinal cord injuries in the US, several technologically advanced spinal cord stimulator devices have been approved by the US Food and Drug Administration. In December 2022, Abbott received the FDA approval for the company's Eterna spinal cord stimulation (SCS) system. It is the smallest implantable, rechargeable spinal cord stimulator available in the market for the treatment of chronic pain.

ClinicalTrails.com, Centers for Disease Control and Prevention (CDC), Food and Drug Administration (FDA), and International Organization for Standardization (ISO) are a few key primary and secondary sources referred to while preparing the report on the spinal cord stimulator device market.